Intravacc, Primrose to advance conjugate vaccine development

2024-03-29

疫苗

Intravacc, Primrose to advance conjugate vaccine development

Preview

来源: Pharmaceutical Technology

The collaboration will offer third parties with a unified solution for vaccine conjugation, manufacturing, and supply. Credit: Ground Picture / Shutterstock.com.

Contract development and manufacturing organisation (CDMO) Intravacc and biotechnology company Primrose Bio have announced a strategic collaboration aimed at bolstering the conjugate vaccine development and supply.

This collaboration is set to provide third parties with a comprehensive solution for vaccine conjugation, manufacturing, and supply, streamlining the process for developers.

Intravacc will provide its extensive technical capabilities, advanced facilities, and expertise in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines.

This expertise is crucial in ensuring the quality and efficacy of vaccines as they progress from concept to commercialisation.

Intravacc CEO Dr Jan Groen said: “We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose’s cutting-edge technologies, we aim to revolutionise the landscape of conjugate vaccine development, ultimately benefiting millions worldwide.”

See Also:

ImmunoGen gets grant for method of preparing cell-binding agent-cytotoxic agent conjugate

Preview

来源: Pharmaceutical Technology

ReAlta signs deal with NIAID to develop drug for radiation poisoning

Preview

来源: Pharmaceutical Technology

Primrose Bio will complement Intravacc’s offerings with its ultra-pure manufacturing, supply chain, and regulatory support for the PeliCRM197 carrier protein.

As a key component in conjugate vaccine formulations, PeliCRM197 is the only commercial CRM197 used in licenced vaccines and is available for purchase.

This carrier protein can be supplied in various quantities and grades, ranging from milligrams to kilograms, catering to both research and GMP applications.

The latest collaboration between the parties represents a strategic alignment with the potential to significantly advance vaccine development.

Primrose Bio CEO Dr Helge Zieler said: “Expanding the capability of our PeliCRM197 franchise with Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development.

“With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole.”